(A and B) Experimental setting for intemittent diet and combination immune checkpoint blockers (cICB) in the RET model and Kaplan Meier curves of overall survival for 12 animals/group, according to therapeutic scheme comparing continuous (Cont) versus intermittent (On/off) diet interventions. (C) Flow cytometric analyses of PD-1 and CTLA-4 expression in splenic CD8+ T lymphocytes at day 17, after diet (ketogenic diet [KD] or 3-hydroxybutyrate [3HB] Cont or On/off) and systemic cICB combinatorial regimen in RENCA bearing BALB/c mice. Refer to Supplemental Figure 5, A and B, for Tim-3, Lag-3, and 4-1BB in all splenic T cells. (D and E) Flow cytometry analysis of MFI for the membrane expression of costimulatory (CD86 in D) or inhibitory (PD-L1 in E) on macrophages (D) and other myeloid subsets from the spleens at day 17, after complete diet (3HB On/off) and systemic cICB combinatorial regimen in RENCA-bearing BALB/c mice. The results from 2–3 experiments involving 6 mice/group are depicted; each dot represents 1 spleen. (F and G) In vitro effects of increasing dosing of 3HB onto a DC cell line stimulated or not with rIFN-γ. Flow cytometry determination of MHC II/I-Ab (F) and PD-L1 expression (G) as mean fluorescence intensity (MFI) on the surface expression at 48 hours of stimulation. One representative experiment out of 4 is depicted, yielding similar conclusions (n = 12 or each groups). Student’s t test (C), global comparison using Kruskall-Wallis test with post hoc multiple comparisons using Dunn’s test (*P < 0.05) (D and E). Global comparison using ANOVA with post hoc multiple comparisons using Dunnett’s test (*P < 0.05) (F and G). *P < 0.05, **P < 0.01, ***P < 0.001.